* pregnancy and breast feeding woman; * postpartum (6 weeks); * extreme weights (\<40 kg or \>100 kg); * patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); * need for therapeutic anticoagulation (except for covid-related pulmonary thrombosis); * bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding * platelet count \< 50 g/l; * within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; * any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; * severe renal failure (creatinine clearance \<30 ml/min); * iodine allergy; * hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; * history of type ii heparin-induced thrombocytopenia; * chronic oxygen supplementation; * moribund patient or death expected from underlying disease during the current admission; * patient deprived of liberty and persons subject to institutional psychiatric care; * patients under guardianship or curatorship; * participation to another interventional research on anticoagulation.

* pregnancy and breast feeding woman; * postpartum (6 weeks); * extreme weights (\<40 kg or \>100 kg); * patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); * need for therapeutic anticoagulation (except for covid-related pulmonary thrombosis); * bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding * platelet count \< 50 g/l; * within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; * any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; * severe renal failure (creatinine clearance \<30 ml/min); * iodine allergy; * hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; * history of type ii heparin-induced thrombocytopenia; * chronic oxygen supplementation; * moribund patient or death expected from underlying disease during the current admission; * patient deprived of liberty and persons subject to institutional psychiatric care; * patients under guardianship or curatorship; * participation to another interventional research on anticoagulation.

pregnancy and breast feeding woman; postpartum (6 weeks); extreme weights (<40 kg or >100 kg); patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); need for therapeutic anticoagulation (except for covid-related pulmonary thrombosis); bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding platelet count < 50 g/l; within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; severe renal failure (creatinine clearance <30 ml/min); iodine allergy; hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; history of type ii heparin-induced thrombocytopenia; chronic oxygen supplementation; moribund patient or death expected from underlying disease during the current admission; patient deprived of liberty and persons subject to institutional psychiatric care; patients under guardianship or curatorship; participation to another interventional research on anticoagulation.

pregnancy and breast feeding woman; postpartum (6 weeks); extreme weights (<40 kg or >100 kg); patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); need for therapeutic anticoagulation (except for covid-related pulmonary thrombosis); bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding platelet count < 50 g/l; within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; severe renal failure (creatinine clearance <30 ml/min); iodine allergy; hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; history of type ii heparin-induced thrombocytopenia; chronic oxygen supplementation; moribund patient or death expected from underlying disease during the current admission; patient deprived of liberty and persons subject to institutional psychiatric care; patients under guardianship or curatorship; participation to another interventional research on anticoagulation.

- pregnancy and breast feeding woman; - postpartum (6 weeks); - extreme weights (<40 kg or >100 kg); - patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); - need for therapeutic anticoagulation; - bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding - platelet count < 50 g/l; - within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; - any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; - severe renal failure (creatinine clearance <30 ml/min); - iodine allergy; - hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; - history of type ii heparin-induced thrombocytopenia; - chronic oxygen supplementation; - moribund patient or death expected from underlying disease during the current admission; - patient deprived of liberty and persons subject to institutional psychiatric care; - patients under guardianship or curatorship; - participation to another interventional research on anticoagulation.

- pregnancy and breast feeding woman; - postpartum (6 weeks); - extreme weights (<40 kg or >100 kg); - patients admitted since more than 72 hours to the hospital (if the who ordinal scale is 5 at time of inclusion) or since more than 72 hours to the intensive care unit (if the who ordinal scale is 6 or more at time of inclusion); - need for therapeutic anticoagulation; - bleeding event related to hemostasis disorders, acute clinically significant bleed, current gastrointestinal ulcer or any organic lesion with high risk for bleeding - platelet count < 50 g/l; - within 15 days of recent surgery, within 24 hours of spinal or epidural anesthesia; - any prior intracranial hemorrhage, enlarged acute ischemic stroke, known intracranial malformation or neoplasm, acute infectious endocarditis; - severe renal failure (creatinine clearance <30 ml/min); - iodine allergy; - hypersensitivity to heparin or its derivatives including low-molecular-weight heparin; - history of type ii heparin-induced thrombocytopenia; - chronic oxygen supplementation; - moribund patient or death expected from underlying disease during the current admission; - patient deprived of liberty and persons subject to institutional psychiatric care; - patients under guardianship or curatorship; - participation to another interventional research on anticoagulation.